Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Bio Farma Recombinant Hepatitis B Vaccine in Adults & Children
NCT04188223Phase 1Completed
- Sponsor
- Bio Farma
- Start
- Dec 2019
- Primary completion
- Jul 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant hepatitis B vaccine Bio Farma in hepatitis B (HBV) (2 arms), sponsored by Bio Farma. Primary endpoints: Number of subjects with Immediate reaction at 3 months and Percentage of subjects with Immediate reaction at 3 months. Started Dec 2019; status: completed.
02
Drugs
recombinant hepatitis B vaccine Bio Farma
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04188223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188223.